AIM ImmunoTech Advances Ampligen Research for Pancreatic Cancer

AIM ImmunoTech has released a new CEO video detailing the scientific rationale and supportive data for its drug Ampligen in the treatment of pancreatic cancer, signaling continued advancement in this therapeutic area.

9 Sept, 13:03 — 9 Sept, 13:03

Post Share

Sources

Showing 1 of 1 sources

taiwan-newsMostly Factual2d ago

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video - taiwannews.com.tw

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video taiwannews.com.tw

Read full article →

AIM ImmunoTech Advances Ampligen Research for Pancreatic Cancer

Sources

AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video - taiwannews.com.tw

Related Stories

UK Parliament Rejects Assisted Dying Bill for Terminally Ill

US Declares End of Largest Cyclosporiasis Outbreak

Ebola Outbreak in DR Congo Spreads to Seventh Province

Princess Kate Visits Hospital Where She Received Cancer Treatment